AR073818A1 - Imidazopiridazinacarbonitrilos utiles como inhibidores de quinasa - Google Patents
Imidazopiridazinacarbonitrilos utiles como inhibidores de quinasaInfo
- Publication number
- AR073818A1 AR073818A1 ARP090103910A ARP090103910A AR073818A1 AR 073818 A1 AR073818 A1 AR 073818A1 AR P090103910 A ARP090103910 A AR P090103910A AR P090103910 A ARP090103910 A AR P090103910A AR 073818 A1 AR073818 A1 AR 073818A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- cr4br4c
- case
- independently selected
- nrara
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Mobile Radio Communication Systems (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Las imidazopiridazinas de formula (1) inhiben la actividad de proteína quinasas haciéndolas utiles como agentes contra el cáncer. Reivindicacion 1: Un compuesto caracterizado porque tiene la formula (1) o una sal farmacéuticamente aceptable del mismo, en el que R1 se selecciona de H, F, Cl, Br, CN, y alquilo C1-6; R2 se selecciona de arilo sustituido con 0-5 R2a y heteroarilo sustituido con 0-5 R2a; R2a, en cada caso, se selecciona independientemente entre H, F, CI, Br, =O, CN, NO2, -ORb, -S(O)pRc, -C(=O)Rd, -NRaRa, -(CR2bR2c)r-C(=O)NRaRa, -NRaC(=O)Rd, -NRaC(=O)ORb, -OC(=O)NRaRa, NRaC(=O)NRaRa, -(CR2bR2c)rC(=O)ORb, -S(O)2NRaRa, -NRaS(O)2NRaRa, -NRaS(O)2Rc, alquilo C1-6 sustituido con 0-5 Re, -(CR2bR2c)r-carbociclilo C3-6 sustituido con 0-5 Re y -(CR2bR2c)r-heterociclilo sustituido con 0-5 Re; R2b, en cada caso, se selecciona independientemente entre H y alquilo C1-6 sustituido con 0-5 Re; R2c, en cada caso, se selecciona independientemente entre H y alquilo C1-6 sustituido con 0-5 Re; R3 se selecciona de H, F, CI, Br, CN, -ORb, -NRaRa, -C(=O)NRaRa, -NRaS(O)2Rc, -NRaC(=O)Rd, -NRaC(=O)ORb, y alquilo C1-6 sustituido con 0-5 Re; R4 se selecciona de H, alquilo C1-6 sustituido con 0-5 Re; -(CR4bR4c)rORb, -(CR4bR4c)rS(O)pRc, -(CR4bR4c)rC(=O)Rd, -(CR4bR4c)rNRaRa, -(CR4bR4c)rC(=O)NRaRa, -(CR4bR4c)rNRaC(=O)Rd, -(CR4bR4c)rNRaC(=O)ORb, -(CR4bR4c)rOC(=O)NRaRa, -(CR4bR4c)rNRaC(=O)NRaRa, -(CR4bR4c)rC(=O)ORb, -(CR4bR4c)rS(O)2NRaRa, -(CR4bR4c)rNRaS(O)2NRaRa, -(CR4bR4c)rNRaS(O)2Rc, -(CR4bR4c)r-carbociclilo C3-6 sustituido con 0-5 R4a, -(CR4bR4c)r-heterociclilo sustituido con 0-5 R4a; R4a, en cada caso, se selecciona independientemente entre F, Cl, Br, alquilo C1-6 sustituido con 0-5 Re, alquenilo C2-6, alquinilo C2-6, NO2, =O, CN, -SO3H, -S(O)pRc, -S(O)2NRaRa, -NRaS(O)2Rc, -ORb, -NRaRa, -NRaC(=O)Rd, -NRaC(=O)NRaRa, -C(=O)ORb, -C(=O)Rd, -OC(=O)Rd, -C(=O)NRaRa, cicloalquilo C3-6, heterociclilo y arilo; R4b en cada caso, se selecciona independientemente entre H y alquilo C1-6 sustituido con 0-5 Re; R4c, en cada caso, se selecciona independientemente entre H y alquilo C1-6 sustituido con 0-5 Re; R5 se selecciona de H y alquilo C1-6 sustituido con 0-5 Re; R6 se selecciona de H y alquilo C1-6 sustituido con 0-5 Re; Ra, en cada caso se selecciona independientemente entre H, CN, alquilo C1-6 sustituido con 0-5 Re, alquenilo C2-6 sustituido con 0-5 Re, alquinilo C2-6 sustituido con 0-5 Re, -(CH2)r-carbociclilo C3-10 sustituido con 0-5 Re y -(CH2)r-heterociclilo sustituido con 0-5 Re; o Ra y Ra junto con el átomo de nitrogeno al que están unidos forman un anillo heterocíclico sustituido con 0-5 Re; Rb, en cada caso, se selecciona independientemente entre H, alquilo C1-6 sustituido con 0-5 Re, alquenilo C2-6 sustituido con 0-5 Re, alquinilo C2-6 sustituido con 0-5 Re, -(CH2)r-carbociclilo C3-10 sustituido con 0-5 Re y -(CH2)r-heterociclilo sustituido con 0-5 Re; Rc, en cada caso, se selecciona independientemente entre alquilo C1-6 sustituido con 0-5 Re, alquenilo C2-6 sustituido con 0-5 Re, alquinilo C2-6 sustituido con 0-5 Re, carbociclilo C3-6 y heterociclilo; Rd, en cada caso, se selecciona independientemente entre H, alquilo C1-6 sustituido con 0-5 Re, alquenilo C2-6 sustituido con 0-5 Re, alquinilo C2-6 sustituido con 0-5 Re, -(CH2)r-carbociclilo C3-10 sustituido con 0-5 Re y -(CH2)r-heterociclilo sustituido con 0-5 Re; Re, en cada caso, se selecciona independientemente entre alquilo C1-6 sustituido con 0-5 Rf, alquenilo C2-6, alquinilo C2-6, -(CH2)r-cicloalquilo C3-6, F, Cl, Br, CN, NO2, =O, CO2H, -(CH2)rO-alquilo C1-5, -(CH2)rOH, SH y -(CH2)rNRfRf; Rf, en cada caso, se selecciona independientemente entre H, alquilo C1-5, cicloalquilo C3-6 y fenilo, o Rf y Rf junto con el átomo de nitrogeno al que están unidos forman un anillo heterocíclico; p, en cada caso, se selecciona independientemente entre 0, 1 y 2; y r, en cada caso, se selecciona independientemente entre 0, 1, 2, 3 y 4.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10404508P | 2008-10-09 | 2008-10-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR073818A1 true AR073818A1 (es) | 2010-12-01 |
Family
ID=41718919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090103910A AR073818A1 (es) | 2008-10-09 | 2009-10-09 | Imidazopiridazinacarbonitrilos utiles como inhibidores de quinasa |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US8252795B2 (es) |
| EP (1) | EP2350081B1 (es) |
| JP (1) | JP5560278B2 (es) |
| KR (1) | KR20110075010A (es) |
| CN (1) | CN102245609B (es) |
| AR (1) | AR073818A1 (es) |
| AU (1) | AU2009302360B2 (es) |
| BR (1) | BRPI0920135A2 (es) |
| CA (1) | CA2739782A1 (es) |
| CL (1) | CL2011000777A1 (es) |
| CO (1) | CO6361936A2 (es) |
| CY (1) | CY1114539T1 (es) |
| DK (1) | DK2350081T3 (es) |
| EA (1) | EA018163B1 (es) |
| ES (1) | ES2426951T3 (es) |
| HK (1) | HK1154002A1 (es) |
| HR (1) | HRP20130787T1 (es) |
| IL (1) | IL211693A (es) |
| MX (1) | MX2011003304A (es) |
| NZ (1) | NZ591712A (es) |
| PE (1) | PE20110411A1 (es) |
| PL (1) | PL2350081T3 (es) |
| PT (1) | PT2350081E (es) |
| SI (1) | SI2350081T1 (es) |
| SM (1) | SMT201300109B (es) |
| TW (1) | TWI491610B (es) |
| WO (1) | WO2010042699A1 (es) |
| ZA (1) | ZA201102423B (es) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5394404B2 (ja) * | 2008-02-06 | 2014-01-22 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼ阻害剤として有用な置換イミダゾピリダジン類 |
| TWI491610B (zh) * | 2008-10-09 | 2015-07-11 | 必治妥美雅史谷比公司 | 作為激酶抑制劑之咪唑并嗒腈 |
| TWI541243B (zh) | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
| US9587033B2 (en) | 2010-11-15 | 2017-03-07 | University Of Florida Research Foundation, Inc. | Therapeutic and diagnostic applications targeting TNK-1 |
| CA2821829A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Intellectual Property Gmbh | Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| CN103370322B (zh) | 2010-12-17 | 2016-02-10 | 拜耳知识产权有限责任公司 | 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的2-取代的咪唑并吡嗪 |
| EP2651944B1 (en) | 2010-12-17 | 2015-09-23 | Bayer Intellectual Property GmbH | Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| EP2701507A1 (en) * | 2011-04-26 | 2014-03-05 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as b-raf inhibitors for treatment of cancer |
| US9512126B2 (en) | 2012-03-14 | 2016-12-06 | Bayer Intellectual Property Gmbh | Substituted imidazopyridazines |
| CA2868302A1 (en) | 2012-03-23 | 2013-09-26 | Dennis M. Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
| TW201414737A (zh) * | 2012-07-13 | 2014-04-16 | 必治妥美雅史谷比公司 | 作爲激酶抑制劑之咪唑并三□甲腈 |
| WO2014020041A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| TW201437211A (zh) * | 2013-03-01 | 2014-10-01 | Bayer Pharma AG | 經取代咪唑并嗒□ |
| HUE033131T2 (en) | 2013-06-11 | 2017-11-28 | Bayer Pharma AG | Derivatives of substituted triazolopyridines |
| KR20160099081A (ko) | 2013-07-26 | 2016-08-19 | 업데이트 파마 인코포레이트 | 비산트렌의 치료 효과 개선용 조합 방법 |
| TW201542550A (zh) * | 2013-09-06 | 2015-11-16 | Lexicon Pharmaceuticals Inc | 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法 |
| AR097543A1 (es) * | 2013-09-06 | 2016-03-23 | Lexicon Pharmaceuticals Inc | COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO |
| GB201403536D0 (en) * | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
| WO2017087590A1 (en) | 2015-11-18 | 2017-05-26 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
| EP3474855B1 (en) | 2016-06-24 | 2022-01-26 | Polaris Pharmaceuticals, Inc. | Ck2 inhibitors, compositions and methods thereof |
| CN109790122B (zh) * | 2016-08-10 | 2022-06-24 | 武田药品工业株式会社 | 杂环化合物 |
| JP7012082B2 (ja) | 2016-11-17 | 2022-01-27 | ブリストル－マイヤーズ スクイブ カンパニー | Ｉｌ－１２、ｉｌ－２３および／またはｉｆｎ－アルファのイミダゾピリダジン調節剤 |
| JP7129420B6 (ja) | 2017-03-30 | 2024-02-02 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｈｐｋ１阻害剤としてのイソキノリン |
| CA3079786A1 (en) | 2017-10-24 | 2019-05-02 | The Broad Institute, Inc. | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
| WO2019128871A1 (zh) | 2017-12-29 | 2019-07-04 | 江苏中旗科技股份有限公司 | N-烷基-n-氰基烷基苯甲酰胺类化合物及其应用 |
| WO2019128872A1 (zh) | 2017-12-29 | 2019-07-04 | 江苏中旗科技股份有限公司 | 一种具有杀虫活性的吡唑酰胺类化合物及其应用 |
| CN109988150B (zh) | 2017-12-29 | 2022-04-12 | 江苏中旗科技股份有限公司 | N-烷基-n-氰基烷基苯甲酰胺类化合物及其应用 |
| CN111867581B (zh) * | 2018-01-29 | 2023-12-26 | 默克专利股份有限公司 | Gcn2抑制剂及其用途 |
| US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
| KR20220002890A (ko) | 2019-03-19 | 2022-01-07 | 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 | 구충성 아자-벤조티오펜 및 아자-벤조푸란 화합물 |
| US20220378762A1 (en) | 2019-04-24 | 2022-12-01 | Bayer Aktiengesellschaft | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
| CN117946100A (zh) | 2019-04-24 | 2024-04-30 | 拜耳股份有限公司 | 4H-吡咯并[3,2-c]吡啶-4-酮化合物 |
| WO2020216773A1 (en) | 2019-04-24 | 2020-10-29 | Bayer Aktiengesellschaft | 4h-pyrrolo[3,2-c]pyridin-4-one compounds |
| WO2021198020A1 (en) | 2020-03-31 | 2021-10-07 | Bayer Aktiengesellschaft | 3-(anilino)-2-[3-(3-alkoxy-pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one derivatives as egfr inhibitors for the treatment of cancer |
| KR20230028268A (ko) | 2020-05-29 | 2023-02-28 | 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 | 구충성 헤테로시클릭 화합물 |
| WO2023147372A1 (en) * | 2022-01-25 | 2023-08-03 | Kinnate Biopharma Inc. | Inhibitors of cdk4/6 kinase |
| WO2024039767A1 (en) * | 2022-08-18 | 2024-02-22 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Imidazo[1,2-b]pyridazine inhibitors of cyclin-dependent kinases |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2263566C (en) | 1996-08-28 | 2003-09-09 | Pfizer Inc. | Substituted 6,5-hetero-bicyclic derivatives |
| CN1173975C (zh) | 2000-04-27 | 2004-11-03 | 山之内制药株式会社 | 咪唑并吡啶衍生物 |
| WO2004017950A2 (en) | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
| HUE033832T2 (en) | 2002-11-15 | 2018-01-29 | Idenix Pharmaceuticals Llc | 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation |
| ATE362475T1 (de) * | 2003-12-31 | 2007-06-15 | Schering Plough Ltd | Bekämpfng von parasiten in tieren durch anwendung von imidazo(1,2-b)pyridazinderivaten |
| WO2005080355A1 (en) | 2004-02-12 | 2005-09-01 | Neurogen Corporation | Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands |
| CN101048158A (zh) * | 2004-08-13 | 2007-10-03 | 健泰科生物技术公司 | 利用atp的酶的噻唑－类抑制剂 |
| EP1832588A4 (en) * | 2004-12-28 | 2009-09-02 | Takeda Pharmaceutical | IMIDAZOLE CONDENSE DERIVATIVE AND APPLICATIONS THEREOF |
| US20070185063A1 (en) | 2005-08-23 | 2007-08-09 | Idenix Pharmaceuticals, Inc. | Seven-membered ring nucleosides |
| US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
| WO2007035428A1 (en) | 2005-09-15 | 2007-03-29 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| US20070078136A1 (en) * | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US7723336B2 (en) * | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US7547782B2 (en) * | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| CL2007002261A1 (es) * | 2006-08-04 | 2008-05-02 | Takeda Pharmaceutical | Compuestos derivados de imidazo[1,2-b]piridazina, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion del cancer. |
| EP1900739A1 (en) | 2006-08-30 | 2008-03-19 | Cellzome Ag | Diazolodiazine derivatives as kinase inhibitors |
| EP2063962A2 (en) | 2006-09-07 | 2009-06-03 | Biogen Idec MA Inc. | Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder |
| WO2008029152A2 (en) | 2006-09-08 | 2008-03-13 | Summit Corporation Plc | Treatment of duchenne muscular dystrophy |
| EP1911451A1 (en) * | 2006-10-10 | 2008-04-16 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Protein-kinase CK2 inhibitors and their therapeutic applications |
| RU2009120388A (ru) * | 2006-10-30 | 2010-12-10 | Новартис АГ (CH) | Имидазопиридазины в качестве ингибиторов липидкиназы |
| MX2009012066A (es) * | 2007-05-09 | 2009-11-19 | Novartis Ag | Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k. |
| JP5394404B2 (ja) * | 2008-02-06 | 2014-01-22 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼ阻害剤として有用な置換イミダゾピリダジン類 |
| TWI491610B (zh) * | 2008-10-09 | 2015-07-11 | 必治妥美雅史谷比公司 | 作為激酶抑制劑之咪唑并嗒腈 |
-
2009
- 2009-10-01 TW TW098133429A patent/TWI491610B/zh not_active IP Right Cessation
- 2009-10-08 MX MX2011003304A patent/MX2011003304A/es active IP Right Grant
- 2009-10-08 EA EA201100580A patent/EA018163B1/ru not_active IP Right Cessation
- 2009-10-08 JP JP2011531168A patent/JP5560278B2/ja not_active Expired - Fee Related
- 2009-10-08 CN CN200980149133.2A patent/CN102245609B/zh not_active Expired - Fee Related
- 2009-10-08 CA CA2739782A patent/CA2739782A1/en not_active Abandoned
- 2009-10-08 NZ NZ591712A patent/NZ591712A/xx not_active IP Right Cessation
- 2009-10-08 PL PL09740573T patent/PL2350081T3/pl unknown
- 2009-10-08 SI SI200930729T patent/SI2350081T1/sl unknown
- 2009-10-08 PE PE2011000814A patent/PE20110411A1/es not_active Application Discontinuation
- 2009-10-08 DK DK09740573.2T patent/DK2350081T3/da active
- 2009-10-08 AU AU2009302360A patent/AU2009302360B2/en not_active Ceased
- 2009-10-08 BR BRPI0920135A patent/BRPI0920135A2/pt not_active IP Right Cessation
- 2009-10-08 WO PCT/US2009/059968 patent/WO2010042699A1/en active Application Filing
- 2009-10-08 PT PT97405732T patent/PT2350081E/pt unknown
- 2009-10-08 ES ES09740573T patent/ES2426951T3/es active Active
- 2009-10-08 KR KR1020117010394A patent/KR20110075010A/ko not_active Application Discontinuation
- 2009-10-08 US US12/575,589 patent/US8252795B2/en active Active
- 2009-10-08 EP EP09740573.2A patent/EP2350081B1/en not_active Not-in-force
- 2009-10-09 AR ARP090103910A patent/AR073818A1/es unknown
-
2011
- 2011-03-10 IL IL211693A patent/IL211693A/en not_active IP Right Cessation
- 2011-03-31 ZA ZA2011/02423A patent/ZA201102423B/en unknown
- 2011-04-07 CL CL2011000777A patent/CL2011000777A1/es unknown
- 2011-04-07 CO CO11043111A patent/CO6361936A2/es active IP Right Grant
- 2011-08-08 HK HK11108272.9A patent/HK1154002A1/xx not_active IP Right Cessation
-
2012
- 2012-07-19 US US13/552,795 patent/US20120283241A1/en not_active Abandoned
-
2013
- 2013-08-20 HR HRP20130787AT patent/HRP20130787T1/hr unknown
- 2013-09-30 CY CY20131100844T patent/CY1114539T1/el unknown
- 2013-10-02 SM SM201300109T patent/SMT201300109B/xx unknown
-
2014
- 2014-02-27 US US14/191,861 patent/US9371328B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR073818A1 (es) | Imidazopiridazinacarbonitrilos utiles como inhibidores de quinasa | |
| AR085318A1 (es) | Derivados de triazol que tienen actividad insecticida | |
| AR109596A1 (es) | Compuestos pirazolopiridina y sus usos | |
| AR109595A1 (es) | Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1 | |
| AR083936A1 (es) | Derivados pirazolicos de bisamida aromaticas, composiciones insecticidas que los contienen y metodos de utilizacion de los mismos para combatir y controlar plagas | |
| AR057960A1 (es) | Inhibidores de proteina quinasa biciclicos | |
| CU20130126A7 (es) | Inhibidores sustituidos de acetil-coa carboxilasa | |
| PE20150339A1 (es) | Carboxamidas heterociclicas fungicidas | |
| ES2677919T3 (es) | Aminoalquil-quinazolonas sustituidas con pirimidina como inhibidores de la fosfatidilinositol 3-quinasa | |
| AR087516A1 (es) | Compuestos de n-tio-antranilamida y sus usos como plaguicidas | |
| ES2569539T3 (es) | Derivados de piperidin-4-il azetidina como inhibidores de JAK1 | |
| AR073327A1 (es) | Heterociclos nitrogenados y su uso como anticancerigenos | |
| AR080531A1 (es) | Derivados de triazol como insecticidas | |
| EA201201178A1 (ru) | Пестицидные смеси, включающие изоксазолиновые производные и инсектицид или нематоцидное биологическое средство | |
| BR112014007847A2 (pt) | derivados de isoxazolina como compostos inseticidas | |
| AR080233A1 (es) | Derivados de dihidrofurano como compuestos insecticidas | |
| PE20141202A1 (es) | Compuesto de ciclopropanoamina | |
| AR094272A1 (es) | Compuestos de diona ciclica activos como herbicidas, o derivados de los mismos, sustituidos por un fenilo que tiene un sustituyente que contiene alquinilo | |
| EA201890872A1 (ru) | Новые алкинилзамещенные 3-фенилпирролидин-2,4-дионы и их применение в качестве гербицидов | |
| AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR072085A1 (es) | Compuestos triciclicos, metodos para su preparacion, composicion farma-ceutica que los comprende y su uso en el tratamiento de enfermedades me-diadas por la actividad de las proteinas quinasas | |
| AR094139A1 (es) | Mezclas activas como plaguicidas, que comprenden compuestos de antranilamida | |
| AR067978A1 (es) | Compuesto de pirridinil bencenosulfonamida, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar la enfermedad pulmonar obstructiva cronica (epoc) | |
| MA35172B1 (fr) | Melanges pestticides contenant des derives d'isoxazoline | |
| AR078270A1 (es) | Inhibidores de jak (quinasas janus) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |